Pub Date : 2025-05-01Epub Date: 2025-07-02DOI: 10.1016/j.ric.2025.100003
Carlos Cantú-Brito, Manuel Alfonso Baños-González, Jesus Antonio González-Hermosillo, Milton Ernesto Guevara-Valdivia, Jorge Abel Vázquez-Acosta, José Luis Leiva-Pons, Alejandro Lechuga-Martin Del Campo, Humberto Rodríguez-Reyes, Janneth Manzano-Cabada, Manlio Fabio Márquez-Murillo, Manuel Odín de Los Ríos-Ibarra, Julio Alberto Aguilar-Linares, Gerardo Pozas-Garza, Eddie Alberto Favela-Pérez, Luis Molina-Fernández de Lara, Reynaldo Magaña Magaña, Rocío Camacho-Casillas, Cesar Vásquez-Serna, Norberto Matadamas-Hernández, Ulises Rojel-Martínez, Miguel Negrete-Rivera, Héctor Fernández-Saldaña, Marco Islava-Galvez, Lidia Betancourt-Hernández, Demetrio Kosturakis-García, Alberto Baños-Velasco, Miguel Beltrán-Gámez, Susano Lara-Vaca, José Luis Novelo-Del Valle, Luis Delgado-Leal, Luis Trujillo-Muñoz, Raúl Isaac-Márquez, Enrique Martínez-Flores, Nicolás Reyes-Reyes, Ramón Miguel Esturau-Santaló, José Fabián Hernández-Díaz, Juan Carlos Núñez-Fragoso, José Manuel Enciso Muñoz, María Isabel Sánchez-Ramírez
Background: Atrial fibrillation (AF) increases the risk of stroke, especially in patients with previous cerebrovascular disease. This risk is significantly reduced with oral anticoagulants (OAC), with direct oral anticoagulants (DOACs) being the optimal treatment.
Objectives: To study the most used anticoagulant treatment in patients with nonvalvular AF (NVAF) with and without cerebrovascular disease in Mexico.
Methods: CARMEN-AF is a national, multicentric observational registry that includes 1423 patients with AF. Patients were recruited regardless of the anticoagulant therapy. Demographics, clinical variables, comorbidities and antithrombotic treatment were compared among patients with and without a history of cerebrovascular disease.
Results: Of the 238 patients with a previous cerebrovascular disease (average age 69±13 years; 114 women [48.5%]), 99% had a previous ischemic stroke. In this subgroup, the type of AF was permanent 43.4%, persistent 20%, and paroxysmal AF was 36.6%. Principal comorbidities were hypertension 77.9%, diabetes mellitus 29.8%, and heart failure 20%. Nearly 12.4% of patients with a history of ischemic cerebrovascular disease did not receive anticoagulant (AC) treatment. Among those who did, vitamin K antagonists (VKAs) were more commonly prescribed than DOACs (37.4% vs. 25.5%).
Conclusion: In Mexico, anticoagulation rates remain low among patients with NVAF and a history of cerebrovascular disease.
{"title":"Suboptimal oral anticoagulation in patients with nonvalvular atrial fibrillation and history of cerebrovascular disease in Mexico. Results from CARMEN-AF Registry.","authors":"Carlos Cantú-Brito, Manuel Alfonso Baños-González, Jesus Antonio González-Hermosillo, Milton Ernesto Guevara-Valdivia, Jorge Abel Vázquez-Acosta, José Luis Leiva-Pons, Alejandro Lechuga-Martin Del Campo, Humberto Rodríguez-Reyes, Janneth Manzano-Cabada, Manlio Fabio Márquez-Murillo, Manuel Odín de Los Ríos-Ibarra, Julio Alberto Aguilar-Linares, Gerardo Pozas-Garza, Eddie Alberto Favela-Pérez, Luis Molina-Fernández de Lara, Reynaldo Magaña Magaña, Rocío Camacho-Casillas, Cesar Vásquez-Serna, Norberto Matadamas-Hernández, Ulises Rojel-Martínez, Miguel Negrete-Rivera, Héctor Fernández-Saldaña, Marco Islava-Galvez, Lidia Betancourt-Hernández, Demetrio Kosturakis-García, Alberto Baños-Velasco, Miguel Beltrán-Gámez, Susano Lara-Vaca, José Luis Novelo-Del Valle, Luis Delgado-Leal, Luis Trujillo-Muñoz, Raúl Isaac-Márquez, Enrique Martínez-Flores, Nicolás Reyes-Reyes, Ramón Miguel Esturau-Santaló, José Fabián Hernández-Díaz, Juan Carlos Núñez-Fragoso, José Manuel Enciso Muñoz, María Isabel Sánchez-Ramírez","doi":"10.1016/j.ric.2025.100003","DOIUrl":"https://doi.org/10.1016/j.ric.2025.100003","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) increases the risk of stroke, especially in patients with previous cerebrovascular disease. This risk is significantly reduced with oral anticoagulants (OAC), with direct oral anticoagulants (DOACs) being the optimal treatment.</p><p><strong>Objectives: </strong>To study the most used anticoagulant treatment in patients with nonvalvular AF (NVAF) with and without cerebrovascular disease in Mexico.</p><p><strong>Methods: </strong>CARMEN-AF is a national, multicentric observational registry that includes 1423 patients with AF. Patients were recruited regardless of the anticoagulant therapy. Demographics, clinical variables, comorbidities and antithrombotic treatment were compared among patients with and without a history of cerebrovascular disease.</p><p><strong>Results: </strong>Of the 238 patients with a previous cerebrovascular disease (average age 69±13 years; 114 women [48.5%]), 99% had a previous ischemic stroke. In this subgroup, the type of AF was permanent 43.4%, persistent 20%, and paroxysmal AF was 36.6%. Principal comorbidities were hypertension 77.9%, diabetes mellitus 29.8%, and heart failure 20%. Nearly 12.4% of patients with a history of ischemic cerebrovascular disease did not receive anticoagulant (AC) treatment. Among those who did, vitamin K antagonists (VKAs) were more commonly prescribed than DOACs (37.4% vs. 25.5%).</p><p><strong>Conclusion: </strong>In Mexico, anticoagulation rates remain low among patients with NVAF and a history of cerebrovascular disease.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 3","pages":"100003"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144976143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2025-06-27DOI: 10.1016/j.ric.2025.100007
Fernanda Cobo, Santiago Cabiedes, Ian Toto, Fernanda Zavala, Gerardo Gamba
Background: The scientific meetings disseminate the results of the latest research. However, if the presented work is not published later, the information is lost.
Objective: To know and compare the fate of the abstracts produced by our nephrology community that were submitted to the Instituto Mexicano de Investigaciones Nefrológicas (IMIN) and American Society of Nephrology (ASN) meetings.
Methods: All abstracts presented by Mexican authors to the ASN from 2011 to 2019 and the IMIN from 2018 to 2019 were analyzed. We captured their publication rate, time to publication, journals, and the impact factor. Publications in both cases were analyzed through PubMed and Scopus databases.
Results: Of the 382 works submitted at ASN by Mexican authors from 2011 to 2019, 141 (36.5%; p<0.001 vs. IMIN) were published. The percentage increases if only accepted abstracts are included (141 of 265, 45%). The format of the presentation affected the final publication rate, which is 81% for free communications, 41.4% for posters, and 18.6% for non-accepted works. In contrast, of the 641 works presented from the 2018-2019 annual meetings of the IMIN, 8% (n=52) have been published.
Conclusion: The publication rate of the ASN abstracts presented by Mexico is like that seen globally for international meetings. However, the publication rate of works presented in our national meeting is very low.
{"title":"The fate of abstracts presented by Mexican authors at the American Society of Nephrology and Mexican meetings: A comparative study.","authors":"Fernanda Cobo, Santiago Cabiedes, Ian Toto, Fernanda Zavala, Gerardo Gamba","doi":"10.1016/j.ric.2025.100007","DOIUrl":"https://doi.org/10.1016/j.ric.2025.100007","url":null,"abstract":"<p><strong>Background: </strong>The scientific meetings disseminate the results of the latest research. However, if the presented work is not published later, the information is lost.</p><p><strong>Objective: </strong>To know and compare the fate of the abstracts produced by our nephrology community that were submitted to the Instituto Mexicano de Investigaciones Nefrológicas (IMIN) and American Society of Nephrology (ASN) meetings.</p><p><strong>Methods: </strong>All abstracts presented by Mexican authors to the ASN from 2011 to 2019 and the IMIN from 2018 to 2019 were analyzed. We captured their publication rate, time to publication, journals, and the impact factor. Publications in both cases were analyzed through PubMed and Scopus databases.</p><p><strong>Results: </strong>Of the 382 works submitted at ASN by Mexican authors from 2011 to 2019, 141 (36.5%; p<0.001 vs. IMIN) were published. The percentage increases if only accepted abstracts are included (141 of 265, 45%). The format of the presentation affected the final publication rate, which is 81% for free communications, 41.4% for posters, and 18.6% for non-accepted works. In contrast, of the 641 works presented from the 2018-2019 annual meetings of the IMIN, 8% (n=52) have been published.</p><p><strong>Conclusion: </strong>The publication rate of the ASN abstracts presented by Mexico is like that seen globally for international meetings. However, the publication rate of works presented in our national meeting is very low.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 3","pages":"100007"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144976081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2025-06-11DOI: 10.1016/j.ric.2025.100001
Alfredo Ulloa-Aguirre, Noemí Del Toro-Cisneros
{"title":"Editorial.","authors":"Alfredo Ulloa-Aguirre, Noemí Del Toro-Cisneros","doi":"10.1016/j.ric.2025.100001","DOIUrl":"https://doi.org/10.1016/j.ric.2025.100001","url":null,"abstract":"","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 3","pages":"100001"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-01Epub Date: 2025-06-30DOI: 10.1016/j.ric.2025.100010
Carlos A Aguilar Salinas
{"title":"Science communication and the role of national academic meetings: A reflection.","authors":"Carlos A Aguilar Salinas","doi":"10.1016/j.ric.2025.100010","DOIUrl":"https://doi.org/10.1016/j.ric.2025.100010","url":null,"abstract":"","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 3","pages":"100010"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Influenza A virus H1N1 is a significant cause of respiratory infections, leading to severe complications in some patients. Understanding the molecular differences between severe and mild cases can provide insights into the pathogenesis and potential therapeutic targets for H1N1 infections.
Objectives: The objectives of the study were to investigate the transcriptional variances in mRNA and lncRNA between severe and mild cases of H1N1 infection to discern potential markers contributing to the severity of the illness.
Methods: Transcriptome sequencing was conducted on PBMC samples from 4 severe and 4 mild H1N1-infected patients. The transcriptional profiles of mRNA and lncRNA were analyzed to identify differential expression patterns between the two groups.
Results: Analysis revealed 3655 differentially expressed genes (DEGs), including 3147 protein-coding genes and 508 lncRNAs, in severe versus mild H1N1 cases. These genes were linked to essential cellular processes like ribosome assembly and significant signaling pathways such as the MAPK signaling cascade.
Conclusion: The identified DEGs, particularly those associated with ribosome assembly and key signaling pathways, may serve as potential biomarkers for distinguishing between severe and mild H1N1 infections. This research sheds light on the distinct transcriptomic features contributing to the pathogenesis of severe H1N1 infections, offering insights into differential diagnosis and potential therapeutic targets.
{"title":"Distinctive features of IncRNA and mRNA between severe and mild patients with influenza a (H1N1) virus pneumonia.","authors":"Dangsheng Xiao, Jinyou Li, Xuehui Zhao, Yongtao Li, Haifeng Lu, Jiezuan Yang","doi":"10.24875/RIC.24000236","DOIUrl":"https://doi.org/10.24875/RIC.24000236","url":null,"abstract":"<p><strong>Background: </strong>Influenza A virus H1N1 is a significant cause of respiratory infections, leading to severe complications in some patients. Understanding the molecular differences between severe and mild cases can provide insights into the pathogenesis and potential therapeutic targets for H1N1 infections.</p><p><strong>Objectives: </strong>The objectives of the study were to investigate the transcriptional variances in mRNA and lncRNA between severe and mild cases of H1N1 infection to discern potential markers contributing to the severity of the illness.</p><p><strong>Methods: </strong>Transcriptome sequencing was conducted on PBMC samples from 4 severe and 4 mild H1N1-infected patients. The transcriptional profiles of mRNA and lncRNA were analyzed to identify differential expression patterns between the two groups.</p><p><strong>Results: </strong>Analysis revealed 3655 differentially expressed genes (DEGs), including 3147 protein-coding genes and 508 lncRNAs, in severe versus mild H1N1 cases. These genes were linked to essential cellular processes like ribosome assembly and significant signaling pathways such as the MAPK signaling cascade.</p><p><strong>Conclusion: </strong>The identified DEGs, particularly those associated with ribosome assembly and key signaling pathways, may serve as potential biomarkers for distinguishing between severe and mild H1N1 infections. This research sheds light on the distinct transcriptomic features contributing to the pathogenesis of severe H1N1 infections, offering insights into differential diagnosis and potential therapeutic targets.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 2","pages":"67-80"},"PeriodicalIF":1.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Super-enhancers (SEs) play a key role in cell fate determination by regulating the transcription of cell-specific target genes and may contribute to the pathogenesis of neurodegenerative diseases. Targeted inhibition of the activity of SEs or knockout of SEs fragments may represent a novel therapeutic strategy for neurodegenerative diseases. This article mainly outlines the discovery, structure, and identification methods of SEs; lists the current SE database platforms; summarizes the main regulatory mechanisms of SEs and strategies to acquire disease-specific SEs; and reviews recent research advances on SEs in neurodegenerative diseases. These findings provide new insights into the molecular mechanisms and development of treatment for neurodegenerative diseases.
{"title":"The mechanism of super-enhancer regulation of gene expression and research progress in neurodegenerative diseases.","authors":"Shaofei Zhao, Qian Yang, Changjun Gao","doi":"10.24875/RIC.24000246","DOIUrl":"https://doi.org/10.24875/RIC.24000246","url":null,"abstract":"<p><p>Super-enhancers (SEs) play a key role in cell fate determination by regulating the transcription of cell-specific target genes and may contribute to the pathogenesis of neurodegenerative diseases. Targeted inhibition of the activity of SEs or knockout of SEs fragments may represent a novel therapeutic strategy for neurodegenerative diseases. This article mainly outlines the discovery, structure, and identification methods of SEs; lists the current SE database platforms; summarizes the main regulatory mechanisms of SEs and strategies to acquire disease-specific SEs; and reviews recent research advances on SEs in neurodegenerative diseases. These findings provide new insights into the molecular mechanisms and development of treatment for neurodegenerative diseases.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 2","pages":"35-43"},"PeriodicalIF":1.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mayra A Arenas-Beltrán, Paula Ruiz-Talero, Karen Navarro-Pérez, Pilar Alarcón-Robles, Alice D Salamanca, Oscar M Muñoz-Velandia
Background: Anticoagulation stewardship in warfarin users reduces thromboembolic and bleeding events and improves adherence. Limited data exist on its impact on adherence among direct oral anticoagulants (DOACs) users.
Objective: To evaluate whether inpatient and outpatient follow-up in an anticoagulation stewardship program improves adherence and clinical outcomes in DOAC users compared to usual care.
Methods: Cohort study of patients initiating DOAC therapy at a university medical center. Participants were categorized into anticoagulation stewardship and usual care cohorts. Adherence was assessed at 30, 90, and 180 days. Univariate and multivariate logistic regression models were used to identify factors associated with lower adherence.
Results: 250 patients were included, with 81 receiving anticoagulation stewardship follow up. Adherence at 30 days was intermediate-high in over 90% of participants. The no-follow-up group showed a higher proportion of patients with low adherence (9.4% versus 2.4%, p = 0.003) and bleeding complications (4.1% versus 0%, p = 0.063). Anticoagulation stewardship exhibited a trend toward higher adherence (odds ratio [OR]: 3.51; 95% confidence interval [CI]: 0.74-16.47; p = 0.107). Factors associated with lower adherence included higher educational level (OR: 0.20; 95% CI: 0.05-0.75; p = 0.018), enrollment in a subsidized health system (OR: 0.08; 95% CI: 0.01-0.64; p = 0.018), and deep venous thrombosis as an indication for anticoagulation.
Conclusion: Anticoagulation stewardship programs may enhance adherence to DOAC therapy. Prospective studies are needed to confirm these findings.
{"title":"Impact on adherence and clinical outcomes of an anticoagulation stewardship program in users of direct oral anticoagulants.","authors":"Mayra A Arenas-Beltrán, Paula Ruiz-Talero, Karen Navarro-Pérez, Pilar Alarcón-Robles, Alice D Salamanca, Oscar M Muñoz-Velandia","doi":"10.24875/RIC.25000008","DOIUrl":"https://doi.org/10.24875/RIC.25000008","url":null,"abstract":"<p><strong>Background: </strong>Anticoagulation stewardship in warfarin users reduces thromboembolic and bleeding events and improves adherence. Limited data exist on its impact on adherence among direct oral anticoagulants (DOACs) users.</p><p><strong>Objective: </strong>To evaluate whether inpatient and outpatient follow-up in an anticoagulation stewardship program improves adherence and clinical outcomes in DOAC users compared to usual care.</p><p><strong>Methods: </strong>Cohort study of patients initiating DOAC therapy at a university medical center. Participants were categorized into anticoagulation stewardship and usual care cohorts. Adherence was assessed at 30, 90, and 180 days. Univariate and multivariate logistic regression models were used to identify factors associated with lower adherence.</p><p><strong>Results: </strong>250 patients were included, with 81 receiving anticoagulation stewardship follow up. Adherence at 30 days was intermediate-high in over 90% of participants. The no-follow-up group showed a higher proportion of patients with low adherence (9.4% versus 2.4%, p = 0.003) and bleeding complications (4.1% versus 0%, p = 0.063). Anticoagulation stewardship exhibited a trend toward higher adherence (odds ratio [OR]: 3.51; 95% confidence interval [CI]: 0.74-16.47; p = 0.107). Factors associated with lower adherence included higher educational level (OR: 0.20; 95% CI: 0.05-0.75; p = 0.018), enrollment in a subsidized health system (OR: 0.08; 95% CI: 0.01-0.64; p = 0.018), and deep venous thrombosis as an indication for anticoagulation.</p><p><strong>Conclusion: </strong>Anticoagulation stewardship programs may enhance adherence to DOAC therapy. Prospective studies are needed to confirm these findings.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 2","pages":"44-54"},"PeriodicalIF":1.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karla A Romero-Mora, María Gómez-Palacio-Schjetnann, Laura L Jiménez-Sánchez, Claudia Alvarado-de la Barrera, Akio Murakami-Ogasawara, Samuel E Schulz-Medina, Santiago Ávila-Ríos
Background: Healthcare workers (HCWs) are at risk of body fluids' exposure.
Objective: The objective of this study was to study the incidence of occupational body fluid exposures in HCW at a tertiary hospital and largest coronavirus disease 2019 (COVID-19) center in Mexico.
Methods: Data on sociodemographics, exposure factors, and vaccination status were collected from questionnaires of HCWs self-reporting exposures (January 2013-December 2022). Hepatitis B and C virus (HBV and HCV) and human immunodeficiency virus (HIV) serology data were retrieved from the laboratory platform. Descriptive statistics and variable associations were analyzed.
Results: Four hundred and eighty-two exposures occurred, 311 in women (64.5%). Exposure incidence was 19.09/1000 person-years; 80% were percutaneous; and 20% were splashes. Median age of exposed HCWs was 21 years (standard deviation = 9.65). Nurses were the most exposed (n = 172, 35.6%), mainly in patients room (n = 223, 46%). About 40.5% of HCW had protective antibody titers to HBV surface antigen (anti-HBs). Self-reported vaccination status and protective anti-HBs titers had poor concordance (kappa = 0.02). One hundred and ninety-seven HCW required HIV post-exposure prophylaxis (40.8%) with no seroconversions. Exposures were highest in 2020 (78 cases, p = 0.001 vs. all years).
Conclusion: A high proportion of HCW lacked protective anti-HBs titers. Increased occupational exposures during the COVID-19 pandemic underline the need for standard precautions, HBV immunization, staff training, and post-exposure protocols to enhance pandemics preparedness.
{"title":"Increased occupational exposure to body fluids in healthcare workers during the COVID-19 pandemic: a retrospective study f.","authors":"Karla A Romero-Mora, María Gómez-Palacio-Schjetnann, Laura L Jiménez-Sánchez, Claudia Alvarado-de la Barrera, Akio Murakami-Ogasawara, Samuel E Schulz-Medina, Santiago Ávila-Ríos","doi":"10.24875/RIC.24000224","DOIUrl":"https://doi.org/10.24875/RIC.24000224","url":null,"abstract":"<p><strong>Background: </strong>Healthcare workers (HCWs) are at risk of body fluids' exposure.</p><p><strong>Objective: </strong>The objective of this study was to study the incidence of occupational body fluid exposures in HCW at a tertiary hospital and largest coronavirus disease 2019 (COVID-19) center in Mexico.</p><p><strong>Methods: </strong>Data on sociodemographics, exposure factors, and vaccination status were collected from questionnaires of HCWs self-reporting exposures (January 2013-December 2022). Hepatitis B and C virus (HBV and HCV) and human immunodeficiency virus (HIV) serology data were retrieved from the laboratory platform. Descriptive statistics and variable associations were analyzed.</p><p><strong>Results: </strong>Four hundred and eighty-two exposures occurred, 311 in women (64.5%). Exposure incidence was 19.09/1000 person-years; 80% were percutaneous; and 20% were splashes. Median age of exposed HCWs was 21 years (standard deviation = 9.65). Nurses were the most exposed (n = 172, 35.6%), mainly in patients room (n = 223, 46%). About 40.5% of HCW had protective antibody titers to HBV surface antigen (anti-HBs). Self-reported vaccination status and protective anti-HBs titers had poor concordance (kappa = 0.02). One hundred and ninety-seven HCW required HIV post-exposure prophylaxis (40.8%) with no seroconversions. Exposures were highest in 2020 (78 cases, p = 0.001 vs. all years).</p><p><strong>Conclusion: </strong>A high proportion of HCW lacked protective anti-HBs titers. Increased occupational exposures during the COVID-19 pandemic underline the need for standard precautions, HBV immunization, staff training, and post-exposure protocols to enhance pandemics preparedness.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"77 2","pages":"55-66"},"PeriodicalIF":1.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Edgar E Lara-Ramírez, Betzaida Cuevas-Córdoba, Diana Olguín-Calderon, Yadira Bastian, César Ramos-Remus, José D Castillo-Ortiz, Martín Zapata-Zúñiga, Jesús Núñez-Contreras, Leendert A Trouw, José A Enciso-Moreno, Julio E Castañeda-Delgado
Background: Rheumatoid arthritis (RA) diagnosis is a challenge in the initial phases of the disease when clinical symptoms are only starting to develop. Early diagnosis and treatment can promote long-term remission, reduce disability, and improve cardiovascular outcomes. Autoantibodies can help in the diagnosis and identification of RA patients in the early phases of the disease, but scarce information has been reported for the Mexican population.
Objective: To study anti-citrullinated peptide antibodies (anti-CCP) and anti-carbamylated protein antibodies (anti-CarP) in Mexican patients with RA and individuals at high risk of developing the disease.
Methods: Serum samples from long-standing and early RA patients, first-degree relatives (FstD) of RA patients, and healthy individuals were analyzed for anti-CCP and anti-CarP using enzyme-linked immunosorbent assay.
Results: Anti-CCP and anti-CarP levels were higher in the RA groups than in the FstD and healthy groups. The odds ratio (OR) for antiCCP for RA groups was 29.7 (95% confidence interval [CI] 14.2-61.9), significantly higher than the OR for anti-CarP 11.07 (95% CI 5.4-22.8). The sensitivity of anti-CCP was 85% (95% CI 76-93) higher than for anti-CarP (42.1%, 95% CI 31-54). The specificity of anti-CarP was 93.8% (95% CI 90-97) and the specificity of anti-CCP was 83.4% (95% CI 78-88). Using both tests in parallel increased sensitivity to 91%, while a sequential approach increased sensitivity to 98%.
Conclusion: Anti-CCP outperformed anti-CarP in Mexican RA patients, demonstrating greater sensitivity, while anti-CarP showed higher specificity. Combining these tests, either simultaneously or sequentially, could enhance diagnostic accuracy. (.
背景:类风湿性关节炎(RA)的诊断是一个挑战,在疾病的初期阶段,临床症状才刚刚开始发展。早期诊断和治疗可以促进长期缓解,减少残疾,改善心血管预后。自身抗体可以帮助RA患者在疾病的早期阶段进行诊断和鉴定,但关于墨西哥人群的信息报道很少。目的:研究墨西哥RA患者及RA高危人群的抗瓜氨酸肽抗体(anti-CCP)和抗氨基甲酰化蛋白抗体(anti-CarP)水平。方法:采用酶联免疫吸附法对长期和早期RA患者、RA患者一级亲属(FstD)和健康人的血清进行抗ccp和抗carp检测。结果:RA组抗ccp和抗carp水平高于FstD组和健康组。RA组anticp的比值比(OR)为29.7(95%可信区间[CI] 14.2-61.9),显著高于anti-CarP的比值比11.07 (95% CI 5.4-22.8)。抗ccp敏感性为85% (95% CI 76-93),高于抗carp敏感性(42.1%,95% CI 31-54)。抗鲤鱼特异性为93.8% (95% CI 90-97),抗ccp特异性为83.4% (95% CI 78-88)。同时使用两种测试可将灵敏度提高到91%,而顺序方法可将灵敏度提高到98%。结论:在墨西哥RA患者中,Anti-CCP优于anti-CarP,具有更高的敏感性,而anti-CarP具有更高的特异性。将这些测试同时或依次结合起来,可以提高诊断的准确性。(.
{"title":"Evaluation of anti-citrullinated and anti-carbamylated antibodies in mexicans with rheumatoid arthritis and at-risk individuals.","authors":"Edgar E Lara-Ramírez, Betzaida Cuevas-Córdoba, Diana Olguín-Calderon, Yadira Bastian, César Ramos-Remus, José D Castillo-Ortiz, Martín Zapata-Zúñiga, Jesús Núñez-Contreras, Leendert A Trouw, José A Enciso-Moreno, Julio E Castañeda-Delgado","doi":"10.24875/RIC.24000181","DOIUrl":"10.24875/RIC.24000181","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) diagnosis is a challenge in the initial phases of the disease when clinical symptoms are only starting to develop. Early diagnosis and treatment can promote long-term remission, reduce disability, and improve cardiovascular outcomes. Autoantibodies can help in the diagnosis and identification of RA patients in the early phases of the disease, but scarce information has been reported for the Mexican population.</p><p><strong>Objective: </strong>To study anti-citrullinated peptide antibodies (anti-CCP) and anti-carbamylated protein antibodies (anti-CarP) in Mexican patients with RA and individuals at high risk of developing the disease.</p><p><strong>Methods: </strong>Serum samples from long-standing and early RA patients, first-degree relatives (FstD) of RA patients, and healthy individuals were analyzed for anti-CCP and anti-CarP using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Anti-CCP and anti-CarP levels were higher in the RA groups than in the FstD and healthy groups. The odds ratio (OR) for antiCCP for RA groups was 29.7 (95% confidence interval [CI] 14.2-61.9), significantly higher than the OR for anti-CarP 11.07 (95% CI 5.4-22.8). The sensitivity of anti-CCP was 85% (95% CI 76-93) higher than for anti-CarP (42.1%, 95% CI 31-54). The specificity of anti-CarP was 93.8% (95% CI 90-97) and the specificity of anti-CCP was 83.4% (95% CI 78-88). Using both tests in parallel increased sensitivity to 91%, while a sequential approach increased sensitivity to 98%.</p><p><strong>Conclusion: </strong>Anti-CCP outperformed anti-CarP in Mexican RA patients, demonstrating greater sensitivity, while anti-CarP showed higher specificity. Combining these tests, either simultaneously or sequentially, could enhance diagnostic accuracy. (.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 6","pages":"243-252"},"PeriodicalIF":1.4,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ailyn Morales-Rentería, Amina Ruiz-Santos, Luis M Amezcua-Castillo, Jazmín A Guerra-López, Kietseé A Díaz-Domínguez, José L Sánchez-Gloria, Héctor González-Pacheco, Luis M Amezcua-Guerra
Background: MiR-155 plays a role in inflammatory pathways and cardiovascular diseases, though its relationship with inflammation, atherosclerosis, and outcomes in ST-elevation myocardial infarction (STEMI) is not well established.
Objective: To investigate associations between miR-155 levels, inflammation, atherosclerotic burden, and major adverse cardiovascular events (MACE) in STEMI patients.
Methods: Sixty-nine STEMI patients and 16 healthy controls were recruited from a specialized university-affiliated cardiovascular center. MiR-155 expression and serum interleukin (IL)-1β, IL-6, and tumor necrosis factor levels were measured. Patients were grouped into tertiles based on miR-155 expression. Clinical data, atherosclerotic burden (through cardiac catheterization), and in-hospital MACE were recorded.
Results: MiR-155 levels were significantly lower in STEMI patients compared to controls (median 54.2, vs. 152.8 arbitrary units; p = 0.003). Higher miR-155 tertiles were associated with a greater prevalence of three-vessel occlusion (34% vs. 13% vs. 4%; p = 0.007) and increased incidence of pulmonary edema (13% vs. 0% vs. 0%; p = 0.030). No significant correlation was found between miR-155 and inflammatory or myocardial markers.
Conclusion: Dysregulated miR-155 expression in STEMI patients may influence disease severity and MACE risk, independent of inflammation or myocardial damage markers.
背景:MiR-155在炎症途径和心血管疾病中发挥作用,尽管其与炎症、动脉粥样硬化和st段抬高型心肌梗死(STEMI)结局的关系尚不清楚。目的:探讨STEMI患者miR-155水平、炎症、动脉粥样硬化负担和主要不良心血管事件(MACE)之间的关系。方法:从某大学附属心血管专科中心招募69例STEMI患者和16例健康对照。检测MiR-155表达、血清白细胞介素(IL)-1β、IL-6和肿瘤坏死因子水平。根据miR-155的表达将患者分组。记录临床资料、动脉粥样硬化负担(通过心导管)和住院MACE。结果:与对照组相比,STEMI患者的MiR-155水平显著降低(中位数为54.2,对152.8任意单位;P = 0.003)。较高的miR-155位数与较高的三支血管闭塞患病率相关(34% vs. 13% vs. 4%;P = 0.007)和肺水肿发生率增加(13% vs. 0% vs. 0%;P = 0.030)。miR-155与炎症或心肌标志物之间无显著相关性。结论:STEMI患者miR-155表达异常可能影响疾病严重程度和MACE风险,与炎症或心肌损伤标志物无关。
{"title":"MIR-155 as a potential biomarker for disease severity in st-segment elevation myocardial infarction: insights from a university-affiliated cardiovascular center.","authors":"Ailyn Morales-Rentería, Amina Ruiz-Santos, Luis M Amezcua-Castillo, Jazmín A Guerra-López, Kietseé A Díaz-Domínguez, José L Sánchez-Gloria, Héctor González-Pacheco, Luis M Amezcua-Guerra","doi":"10.24875/RIC.24000189","DOIUrl":"10.24875/RIC.24000189","url":null,"abstract":"<p><strong>Background: </strong>MiR-155 plays a role in inflammatory pathways and cardiovascular diseases, though its relationship with inflammation, atherosclerosis, and outcomes in ST-elevation myocardial infarction (STEMI) is not well established.</p><p><strong>Objective: </strong>To investigate associations between miR-155 levels, inflammation, atherosclerotic burden, and major adverse cardiovascular events (MACE) in STEMI patients.</p><p><strong>Methods: </strong>Sixty-nine STEMI patients and 16 healthy controls were recruited from a specialized university-affiliated cardiovascular center. MiR-155 expression and serum interleukin (IL)-1β, IL-6, and tumor necrosis factor levels were measured. Patients were grouped into tertiles based on miR-155 expression. Clinical data, atherosclerotic burden (through cardiac catheterization), and in-hospital MACE were recorded.</p><p><strong>Results: </strong>MiR-155 levels were significantly lower in STEMI patients compared to controls (median 54.2, vs. 152.8 arbitrary units; p = 0.003). Higher miR-155 tertiles were associated with a greater prevalence of three-vessel occlusion (34% vs. 13% vs. 4%; p = 0.007) and increased incidence of pulmonary edema (13% vs. 0% vs. 0%; p = 0.030). No significant correlation was found between miR-155 and inflammatory or myocardial markers.</p><p><strong>Conclusion: </strong>Dysregulated miR-155 expression in STEMI patients may influence disease severity and MACE risk, independent of inflammation or myocardial damage markers.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":" ","pages":"013-025"},"PeriodicalIF":1.4,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}